GILD34:BVMF
Gilead Sciences Inc BDR
65,81 BRL
0,00%
(0,00) 1D
16. lis, 16:56:00 GMT -3 · BRL
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za GILD34...
Otvori
66,36 BRL
Najviša
66,41 BRL
Najniža
65,81 BRL
Trž. kap.
193,67 mlr.
Prosj. kol.
261,00
Količina
1,78 tis.
52-tjed. najviša
67,38 BRL
52-tjed. najniža
51,33 BRL
Dionice u optjecaju
1,24 mlr.
Broj djelatnika
17 tis.
Otvori
66,36 BRL
Najviša
66,41 BRL
Najniža
65,81 BRL
Trž. kap.
193,67 mlr.
Prosj. kol.
261,00
Količina
1,78 tis.
52-tjed. najviša
67,38 BRL
52-tjed. najniža
51,33 BRL
Dionice u optjecaju
1,24 mlr.
Broj djelatnika
17 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Yahoo Finance
·
prije 11 sati
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
ad-hoc-news.de
·
prije 12 sati
Gilead Sciences stock trades 0.32 percent above its Xetra close
Simply Wall Street
·
prije 1 dan
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
MarketBeat
·
prije 1 dan
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences Inc BDR – informacije
Glavni izvršni direktorDaniel O'Day
Zaposlenici17 tis.
Osnovano22. lip 1987.
SjedišteFoster City, Kalifornija, Sjedinjene Američke Države
Sektor-
Web-lokacijagilead.com